Delivery Order SPE2DB20D7059-SPE2DB25FPYZ4

Award Date 1/28/25
Potential Completion Date 1/29/25
Potential Value $2.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of lisdexamfetamine 30 mg capsules. The $1,345.44 firm fixed price contract has a completion date of February 10, 2025. It was awarded on February 7, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,774.62, is for the delivery of lisdexamfetamine 10 mg capsules in 100-count packages. The contract has an ultimate completion date of February 11, 2025 and is a firm-fixed-price delivery order. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,355.83 firm fixed-price delivery order is for the supply of 4,567,074,436 units of the medication lisdexamfetamine 40 mg capsule. The contract has an ultimate completion date of January 29, 2025 and was awarded on January 28, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,426.88, is for the delivery of 4567342796 lisdexamfetamine 30 mg capsules in 100-count packages. The contract is a Firm Fixed Price Delivery Order, with a completion date of February 24, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,426.88, is for the delivery of 4,567,422,819 units of 40 mg lisdexamfetamine capsules. The contract is a Firm Fixed Price Delivery Order with a period of performance through March 3, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,489,427 units of the medication Lisdexamfetamine 30mg capsules, valued at $2,972.07. The contract is a Firm Fixed Price Delivery Order with a completion date of March 7, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,288.12 firm-fixed-price delivery order is for the supply of 4,566,988,440 units of the medication Lisdexamfetamine 40 mg capsules. The award has an ultimate completion date of January 21, 2025 and is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,516.41 firm fixed-price delivery order is for the supply of 4,567,299,205 units of the pharmaceutical drug lisdexamfetamine 20 mg capsules. The contract has an ultimate completion date of February 14, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,448.61, is for the delivery of lisdexamfetamine 40 mg capsules in quantities of 100s. The contract has an ultimate completion date of January 14, 2025 and is a firm fixed-price delivery order. There is no set-aside designation for this award. AmerisourceBergen holds a significant Indefinite...
This federal contract award is a delivery order from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,686.15 firm fixed-price contract is for the delivery of 4,567,031,162 units of the prescription medication lisdexamfetamine 30 mg capsules. The contract has an ultimate completion date of January 24, 2025 and was awarded on January 23, 2025. It is not designated as a set-aside contract....
  • SPE2DB20D7059
    Indefinite Delivery Contract
  • SPE2DB20D7059-SPE2DB25FPYZ4
    Delivery Order

This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of lisdexamfetamine 40 mg capsules. The fixed-price, $2,140.32 contract has a completion date of January 29, 2025 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024 for similar medical commodities.

Generated 4/29/25, 9:43 AM